A Multicentre, Open-Label, Long-Term, Safety and Tolerability Study of Retigabine Immediate Release (IR) in Adults With Partial-Onset Seizures (Extension of Study RGB113905)
Phase of Trial: Phase III
Latest Information Update: 07 Jul 2018
At a glance
- Drugs Retigabine (Primary) ; Antiepileptic drugs
- Indications Complex partial epilepsy; Partial epilepsies
- Focus Adverse reactions
- Sponsors GlaxoSmithKline
- 31 Aug 2018 Biomarkers information updated
- 30 Sep 2017 Status changed from active, no longer recruiting to completed.
- 25 Aug 2017 Planned End Date changed from 28 Aug 2017 to 30 Sep 2017.